2 years ago
NTLA
AnalystsGreg HarrisonGreg Harrison's Stock Forecasts
AnalystsGreg Harrison
Analyst Ranking
Top 22%
#1065 out of 4937 analysts
Average Return
+5.54%
Win Rate
49%35 out of 71
Risk vs Reward
Poor
Good
Greg Harrison's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iveric Bio IncISEE | +244.89% | $11.25 | $38.80 | 2022-06-08 - 2023-06-07 | Strong Buy |
Liquidia CorpLQDA | +117.00% | $4.03 | $8.75 | 2022-05-26 - 2023-05-25 | Strong Buy |
Rocket Pharmaceuticals IncRCKT | +96.61% | $21.84 | $42.94 | 2020-06-25 - 2021-06-25 | Strong Buy |
Bridgebio Pharma IncBBIO | +95.91% | $23.72 | $46.47 | 2024-11-15 - 2025-07-11 | Buy |
Travere Therapeutics IncTVTX | +93.76% | $7.85 | $15.21 | 2023-09-22 - 2024-09-20 | Strong Buy |
Greg Harrison Analyst Color
Get additional color on Greg Harrison's coverage of popular stocks
Greg Harrison's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Arcturus Therapeutics Holdings IncARCT | 2 | Buy | $35.00 | +153.99% | Maintains | 11 days ago |
United Therapeutics CorpUTHR | 3 | Hold | $315.00 | +6.59% | Maintains | a month ago |
Rocket Pharmaceuticals IncRCKT | 7 | Buy | $19.00 | +541.89% | Maintains | a month ago |
Liquidia CorpLQDA | 6 | Buy | $37.00 | +162.60% | Maintains | a month ago |
Keros Therapeutics IncKROS | 6 | Buy | $26.00 | +80.06% | Maintains | 2 months ago |
Vera Therapeutics IncVERA | 2 | Buy | $55.00 | +130.90% | Maintains | 2 months ago |
Apellis Pharmaceuticals IncAPLS | 4 | Hold | $20.00 | +2.88% | Maintains | 2 months ago |
Geron CorpGERN | 3 | Hold | $1.50 | +13.64% | Downgrades | 2 months ago |
Vertex Pharmaceuticals IncVRTX | 6 | Hold | $442.00 | -5.73% | Maintains | 2 months ago |
Agios Pharmaceuticals IncAGIO | 5 | Buy | $71.00 | +81.82% | Maintains | 2 months ago |
Bridgebio Pharma IncBBIO | 6 | Buy | $55.00 | +18.36% | Maintains | 2 months ago |
Alnylam Pharmaceuticals IncALNY | 5 | Buy | $342.00 | +8.59% | Maintains | 3 months ago |
Beam Therapeutics IncBEAM | 5 | Buy | $40.00 | +89.04% | Upgrades | 4 months ago |
Disc Medicine IncIRON | 4 | Buy | $75.00 | +31.79% | Maintains | 4 months ago |
Travere Therapeutics IncTVTX | 5 | Buy | $32.00 | +94.29% | Maintains | 5 months ago |
Eyepoint Pharmaceuticals IncEYPT | 1 | Buy | $18.00 | +73.75% | Initiates Coverage On | 9 months ago |
Ocular Therapeutix IncOCUL | 1 | Buy | $22.00 | +99.46% | Initiates Coverage On | 9 months ago |
Intellia Therapeutics IncNTLA | 2 | Strong Buy | $91.00 | N/A | Maintains | 2 years ago |
Stoke Therapeutics IncSTOK | 3 | Hold | $12.00 | N/A | Upgrades | 2 years ago |
Sangamo Therapeutics IncSGMO | 1 | Sell | $1.50 | N/A | Downgrades | 2 years ago |
Mineralys Therapeutics IncMLYS | 1 | Strong Buy | $39.00 | N/A | Initiates Coverage On | 2 years ago |
Editas Medicine IncEDIT | 2 | Hold | $15.00 | N/A | Maintains | 3 years ago |
Omeros CorpOMER | 1 | Sell | $3.00 | N/A | Downgrades | 3 years ago |
Senti Biosciences IncSNTI | 1 | Strong Buy | $70.00 | N/A | Initiates Coverage On | 3 years ago |
Neurogene IncNGNE | 2 | Sell | $5.00 | N/A | Downgrades | 3 years ago |
Radius Health IncRDUS1 | 1 | Hold | $8.00 | N/A | Upgrades | 3 years ago |
Iveric Bio IncISEE | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | 3 years ago |
Athersys IncATHXQ | 4 | Sell | $6.25 | N/A | Downgrades | 3 years ago |
Sentinelone IncS | 1 | Strong Buy | $54.00 | N/A | Maintains | 3 years ago |
Nektar TherapeuticsNKTR | 5 | Sell | $90.00 | N/A | Downgrades | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.